Fabry's disease is an inherited condition that develops due to a mutation in the GLA gene. For most patients with this disease, the mutation causes the body to produce insufficient amounts of ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while ...

Impilo's prototype platform scours medical records to pinpoint symptoms of unusual illnesses that are often overlooked by ...

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

Genzyme anticipates supply constraints of Cerezyme (imiglucerase), a treatment for Gaucher disease, and Fabrazyme (agalsidase beta), used to treat Fabry disease, while the facility shuts down for ...

Reports Q4 revenue $7.6M, consensus $11.7M. “I am pleased with Sangamo’s (SGMO) pipeline progress since the start of 2024. We advanced our two ...